(FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q9)Sep 30, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -22.65%225.07B | -17.23%188.4B | -15.66%134.06B | -17.60%66.28B | -2.64%290.99B | 16.77%227.62B | 31.57%158.96B | 52.77%80.44B | 60.70%298.89B | 46.39%194.93B |
Operating income | -22.65%225.07B | -17.23%188.4B | -15.66%134.06B | -17.60%66.28B | -2.64%290.99B | 16.77%227.62B | 31.57%158.96B | 52.77%80.44B | 60.70%298.89B | 46.39%194.93B |
Cost of sales | 23.95%-197.5B | ---- | 13.06%-122.06B | ---- | 1.69%-259.7B | ---- | -29.33%-140.4B | ---- | -52.11%-264.17B | ---- |
Operating expenses | 23.95%-197.5B | 16.88%-167.06B | 13.06%-122.06B | 16.90%-60.24B | 1.69%-259.7B | -16.01%-200.98B | -29.33%-140.4B | -52.93%-72.49B | -52.11%-264.17B | -41.03%-173.24B |
Gross profit | -11.87%27.57B | -19.88%21.34B | -35.32%12.01B | -23.95%6.04B | -9.89%31.28B | 22.82%26.64B | 51.37%18.56B | 51.32%7.95B | 181.87%34.72B | 110.32%21.69B |
Selling expenses | ---- | -21.52%-326.29M | ---- | 0.14%-96.43M | ---- | -20.17%-268.51M | ---- | -15.99%-96.57M | ---- | 80.13%-223.45M |
Administrative expenses | 1.82%-5.9B | 2.74%-2.85B | 7.30%-2.71B | 0.62%-920.06M | 5.02%-6.01B | -7.98%-2.93B | -23.79%-2.92B | -19.82%-925.79M | -52.14%-6.33B | -31.92%-2.72B |
Research and development expenses | 22.39%-3.73B | -22.63%-3.33B | -1.35%-1.69B | -9.80%-459.85M | -98.77%-4.81B | -123.95%-2.72B | -153.49%-1.67B | -173.48%-418.8M | -68.57%-2.42B | -78.48%-1.21B |
Profit from asset sales | ---- | -96.26%5.13M | ---- | 102.14%379K | ---- | 326.19%137.13M | ---- | -178.14%-17.74M | ---- | 218.04%32.18M |
Revaluation surplus | ---- | -253.21%-84.1M | ---- | -100.00%1K | ---- | 202.18%54.89M | ---- | 909.51%75.99M | ---- | -293.40%-53.72M |
-Changes in the fair value of other assets | ---- | -253.21%-84.1M | ---- | -100.00%1K | ---- | 202.18%54.89M | ---- | 909.51%75.99M | ---- | -293.40%-53.72M |
Impairment and provision | 89.27%-451.89M | 102.85%89.56M | 110.84%233.12M | 74.04%-40.54M | 22.84%-4.21B | -61.02%-3.15B | -350.02%-2.15B | 75.60%-156.14M | -290.79%-5.46B | -30.67%-1.95B |
-Impairment of property, machinery and equipment | 84.25%-597.64M | ---- | ---- | ---- | 6.62%-3.8B | ---- | ---2.1B | ---- | -875.11%-4.06B | ---- |
-Other impairment is provision | 135.19%145.75M | 102.85%89.56M | 562.55%233.12M | 74.04%-40.54M | 70.22%-414.14M | -61.02%-3.15B | 89.46%-50.4M | 75.60%-156.14M | -42.04%-1.39B | -30.67%-1.95B |
Special items of operating profit | 15.98%153.37M | 60.93%575.35M | 16.65%244.65M | 844.61%251.92M | 107.14%132.24M | 234.95%357.52M | 119.29%209.73M | 78.84%-33.83M | -354.35%-1.85B | -134.30%-264.93M |
Adjustment items of operating profit | ---- | ---- | ---- | ---1K | ---- | ---- | ---- | ---- | ---- | ---- |
Operating profit | 7.63%17.64B | -15.74%13.44B | -32.81%8.09B | -24.84%4.2B | -12.18%16.39B | 16.26%15.95B | 59.46%12.03B | 84.26%5.58B | 208.22%18.67B | 194.91%13.72B |
Financing income | -17.18%395.18M | ---- | -24.99%160.59M | ---- | 53.37%477.14M | ---- | 95.43%214.09M | ---- | 36.93%311.1M | ---- |
Financing cost | 14.28%-3.34B | 12.76%-2.24B | 17.59%-1.64B | 17.10%-817.42M | 14.07%-3.89B | 9.38%-2.57B | 1.90%-1.99B | -1.37%-986M | -2.54%-4.53B | 9.64%-2.83B |
Share of profits of associates | 53.84%200.97M | ---- | 142.53%34.62M | ---- | 130.86%130.63M | ---- | -122.89%-81.41M | ---- | -390.42%-423.25M | ---- |
Share of profit from joint venture company | 6.14%189.89M | ---- | -6.27%77.72M | ---- | 9.02%178.91M | ---- | 11.71%82.92M | ---- | -9.09%164.1M | ---- |
Special items of earning before tax | ---- | 33.70%-144.22M | ---- | 198.57%69.26M | ---76M | 72.16%-217.51M | ---- | -95.76%-70.26M | ---- | -406.38%-781.19M |
Adjustment items of earning before tax | ---- | ---- | ---- | ---- | ---- | --1K | ---- | ---- | ---- | ---- |
Earning before tax | 14.24%15.09B | -16.02%11.06B | -34.51%6.72B | -23.83%3.45B | -6.89%13.21B | 30.27%13.17B | 69.34%10.26B | 123.94%4.53B | 548.00%14.19B | 640.67%10.11B |
Tax | -5.97%-2.51B | 14.15%-1.86B | 27.11%-1.13B | 36.61%-546.62M | 17.57%-2.37B | -7.17%-2.16B | -24.68%-1.55B | -90.79%-862.33M | -386.35%-2.87B | -405.08%-2.02B |
After-tax profit from continuing operations | 16.05%12.58B | -16.39%9.2B | -35.83%5.59B | -20.82%2.9B | -4.18%10.84B | 36.04%11B | 80.92%8.71B | 133.49%3.66B | 607.64%11.32B | 738.32%8.09B |
Earning after tax | 16.05%12.58B | -16.39%9.2B | -35.83%5.59B | -20.82%2.9B | -4.18%10.84B | 36.04%11B | 80.92%8.71B | 133.49%3.66B | 607.64%11.32B | 738.32%8.09B |
Minority profit | -11.80%5.87B | -31.35%3.85B | -48.95%2.17B | -34.23%1.09B | 19.68%6.65B | 101.53%5.61B | 147.38%4.25B | 181.33%1.65B | 565.61%5.56B | 459.01%2.78B |
Profit attributable to shareholders | 60.23%6.72B | -0.85%5.35B | -23.32%3.42B | -9.78%1.81B | -27.21%4.19B | 1.72%5.4B | 44.01%4.46B | 104.82%2.01B | 653.55%5.76B | 1,035.68%5.31B |
Basic earnings per share | 63.60%0.391 | -0.32%0.309 | -23.55%0.198 | -9.48%0.105 | -26.69%0.239 | 2.31%0.31 | 47.16%0.259 | 110.91%0.116 | 986.67%0.326 | 1,920.00%0.303 |
Diluted earnings per share | 63.18%0.39 | -0.32%0.309 | -23.55%0.198 | -9.48%0.105 | -26.69%0.239 | 2.31%0.31 | 47.16%0.259 | 110.91%0.116 | 986.67%0.326 | 1,920.00%0.303 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) |
Audit Opinions | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data